BioRestorative Therapies, Inc.
BRTX Nasdaq· Services-Misc Health & Allied Services, Nec
Last close · Oct 26, 2026
$1.58
KIRA · Stoqly’s AI analyst, in plain words
- BioRestorative Therapies, Inc. had $0.4M of revenue in fiscal 2025, down 10.3% on the year before. Over five years, revenue changed +36.1% a year on average.
- Its operating margin was −4,350.0%, down 1,468.4 pts: of every 100 in sales, about −4,350 is left after running the business.
- BioRestorative Therapies, Inc. lost $14.2M in fiscal 2025.
- Free cash flow was −$10.9M in fiscal 2025, −3,031.7% of revenue.
- BioRestorative Therapies, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 15.8%.
Market cap
$28.0M
P/E
—
Revenue
$0.4M
Net income
−$14.2M
Free cash flow
−$10.9M
Operating margin
−4,350.0%
BioRestorative Therapies, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−10.3%
No. Sales fell 10.3% last year.
Does it make a profit?
−3,959.4%
No. It lost money last year.
Does profit turn into cash?
−3,031.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What BioRestorative Therapies, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- BioRestorative Therapies, Inc.
- CIK
- 0001505497
BioRestorative Therapies, Inc. · BRTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.1M | $0.1M | $0.4M | $0.4M |
| Revenue growth | −40.3% | 160.4% | 21.7% | 175.0% | −10.3% |
| Net interest income | −$1.8M | $0.0M | $0.6M | $0.6M | $0.3M |
| Gross margin | — | — | 100.0% | 93.0% | 93.4% |
| Operating margin | −57,191.1% | −15,838.1% | −10,439.5% | −2,881.6% | −4,350.0% |
| Net income | −$44.3M | −$13.2M | −$10.4M | −$9.0M | −$14.2M |
| Net margin | −96,311.5% | −11,037.0% | −7,145.2% | −2,239.3% | −3,959.4% |
| Diluted EPS | −$37.30 | −$3.65 | −$2.47 | −$1.16 | −$1.58 |
| Cash | |||||
| Cash from operations | −$3.3M | −$5.9M | −$6.4M | −$8.2M | −$10.8M |
| Capital expenditure | $0.0M | $0.3M | $0.2M | $0.1M | $0.1M |
| Free cash flow | −$3.4M | −$6.2M | −$6.6M | −$8.3M | −$10.9M |
| FCF margin | −7,305.7% | −5,157.2% | −4,527.6% | −2,078.9% | −3,031.7% |
| Share buybacks | — | — | — | — | $0.0M |
| Share count change | 200.9% | 204.6% | 16.6% | 84.1% | 15.8% |
| Debt and strength | |||||
| Cash and short-term investments | $21.0M | $14.7M | $11.1M | $10.7M | $3.0M |
| Debt incl. finance leases | $0.3M | — | — | — | — |
| Shareholders' equity | $10.8M | $10.3M | $10.0M | $8.5M | $0.4M |
| Current ratio | 59.0x | 2.5x | 4.4x | 3.0x | 0.8x |
| Returns and quality | |||||
| Return on equity | −937.5% | −125.5% | −102.7% | −96.9% | −320.5% |
| Return on tangible equity | −434.6% | −139.4% | −112.1% | −113.6% | — |
| Piotroski F-score | 3 | 3 | 3 | 3 | 3 |
| Altman Z'' | −8.0 | −29.4 | −37.4 | −41.3 | −162.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioRestorative Therapies, Inc. · BRTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.58 a share, the company is worth $28.0M.
Source: SEC EDGAR XBRL filings (CIK 0001505497). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.